AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7785746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, administered four times daily (n=146) for PAC
Trial: 7785746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, administered twice daily (n=677) for SAC
Trial: 7785746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, administered four times daily for SAC
Trial: 2204243
Drug: Bivalent Salmonella
RxNorm normalized name: Salmonella typhi Ty21a live antigen Delayed Release Oral Capsule [Vivotif]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent Salmonella typhi-Shigella sonnei vaccine, 3 doses of 10^9 organisms each
Trial: 31023272
Drug: Brazilian green
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian green propolis extract at a dose of 500 mg/day for 12 months
Trial: 27891757
Drug: Alogliptin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin alone (25 mg once daily)
Trial: 27891757
Drug: Alogliptin/metformin once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin/metformin once daily (500 mg once daily)
Trial: 27891757
Drug: Alogliptin/metformin twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin/metformin twice daily (250 mg twice daily)
Trial: 27891757
Drug: Alogliptin/metformin once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin/metformin once daily
Trial: 25540059
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once daily starting 3 days preoperatively and continuing within 5 days postoperatively
Trial: 22528588
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg/day (600 IU/day) for 8 weeks (Group A)
Trial: 22528588
Drug: Baseline values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline values (Group A before treatment)
Trial: 22147126
Drug: introducer PEG-gastropexy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: introducer PEG-gastropexy technique without antibiotics
Trial: 22147126
Drug: pull PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pull PEG with antibiotics
Trial: 17074945
Drug: Integrated psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated psychological and nicotine replacement therapy intervention (8 sessions)
Trial: 15636169
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (SP) supplementation (40 g daily for 3 months)
Trial: 7970122
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 3 months (group NL)
Trial: 7970122
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 48 h followed by placebo for 3 months (group NS)
Trial: 364631
Drug: Emepronium bromide
RxNorm normalized name: emepronium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium bromide (100 mg in 100 ml saline solution)
Trial: 364631
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (100 ml)
Trial: 27860410
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg every 2 weeks
Trial: 23464532
Drug: AZD1656 10-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 10-140 mg
Trial: 23464532
Drug: AZD1656 20-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 20-200 mg
Trial: 23464532
Drug: Glipizide 5-20
RxNorm normalized name: glipizide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide 5-20 mg
Trial: 23464532
Drug: Open-label AZD1656
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label AZD1656 20-200 mg
Trial: 19041436
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 mcg + CMA 2 mg (Belara)
Trial: 19041436
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 mcg + Desogestrel 0.15 mg (Marvelon)
Trial: 16954556
Drug: 111In-DTPA-D-Phe1-octreotide therapy
RxNorm normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 111In-DTPA-D-Phe1-octreotide therapy
Trial: 16954556
Drug: Transhepatic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transhepatic administration of 111In-DTPA-D-Phe1-octreotide
Trial: 7684579
Drug: HMW‐HES (high‐molecular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMW‐HES (high‐molecular weight hydroxyethyl starch solution)
Trial: 3107331
Drug: Rectal thiopentone
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal thiopentone 30 mg X kg‐1
Trial: 3107331
Drug: Methohexitone 20
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 20 mg X kg‐1
Trial: 3107331
Drug: Methohexitone 30
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 30 mg X kg‐1
Trial: 2050997
Drug: 55 s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55 s.c. injection course of 5 M unit recombinant human alpha‐interferon (group 1, 14 patients)
Trial: 2050997
Drug: Adenine‐arabinoside (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenine‐arabinoside (for 21 days) combined from the fourteenth day on with the same 55 s.c. injection schedule of interferon (group 2, 15 cases)
Trial: 6407408
Drug: Mitomycin C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin C, 20 mg/m2 I.V. direct once every 6 weeks, four courses
Trial: 17631795
Drug: Manipulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation treatment
Trial: 15200444
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hemodialysis
Trial: 12759208
Drug: Conventional vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional vein harvest and storage in a crystalloid solution
Trial: 12759208
Drug: Endoscopic vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic vein harvest and storage in crystalloid solution
Trial: 12759208
Drug: Conventional harvest
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional harvest under continuous perfusion of the vein with 100 ml blood via the heart lung machine
Trial: 9422580
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment with increased radiation doses
Trial: 7866003
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza composite injection (SMCo)
Trial: 2502567
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% mupirocin ointment, applied three times a day for seven days
Trial: 2502567
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% fusidic acid ointment, applied three times a day for seven days
Trial: 25886378
Drug: Capecitabine (CAP)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks with Bevacizumab (BEV) 5 mg/kg once every 2 weeks (3 doses)
Trial: 25886378
Drug: Capecitabine (CAP)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks without Bevacizumab (BEV)
Trial: 22968823
Drug: Subconjunctival triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival triamcinolone injection (20 mg, 1-3 injections at 3-week intervals)
Trial: 21480416
Drug: Astaxanthin 5
RxNorm normalized name: astaxanthin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 5 mg once daily for 3 weeks
Trial: 21480416
Drug: Astaxanthin 20
RxNorm normalized name: Astaxanthin 200mcg, Krill oil 1,000mg, Phospholipid 400mg Oral capsule, liquid filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 20 mg once daily for 3 weeks
Trial: 15031516
Drug: Okavax (varicella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okavax (varicella vaccine)
Trial: 15031516
Drug: Trimovax (MMR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimovax (MMR vaccine)
Trial: 15031516
Drug: Okavax and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okavax and Trimovax administered concomitantly
Trial: 15031516
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of Okavax and Trimovax
Trial: 7794307
Drug: Fluconazole 3
RxNorm normalized name: Fluconazole 3 mg/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 3 mg/kg once daily
Trial: 9462438
Drug: Nystatin 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin 50,000 units/kg/day in four divided doses
Trial: 7935145
Drug: Barrier creams
RxNorm normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier creams
Trial: 7935145
Drug: Hydrocarbon cream
RxNorm normalized name: PARAFFIN HYDROCARBONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocarbon cream
Trial: 3127585
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) treatment
Trial: 28689511
Drug: Group PM+
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group PM+ intervention (five weekly sessions of 2 hours duration delivered by local non-specialist females under supervision)
Trial: 29871263
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray combined with oral montelukast
Trial: 29871263
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray alone
Trial: 23802989
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy in addition to the standard rehabilitation program
Trial: 17117294
Drug: Adequate calcium
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate calcium intake (1000-1500 mg/d) from dairy foods
Trial: 1430299
Drug: Intravenous cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefprozil 250 mg
Trial: 1430299
Drug: Intravenous cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefprozil 500 mg
Trial: 1430299
Drug: Intravenous cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefprozil 1000 mg
Trial: 1430299
Drug: Oral cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefprozil 500 mg
Trial: 2864374
Drug: Beta-blocker (oxprenolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (oxprenolol) treatment
Trial: 27664491
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day resveratrol capsules
Trial: 29885904
Drug: Ziprasidone 20
RxNorm normalized name: ziprasidone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20 mg
Trial: 10536125
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg once daily)
Trial: 10536125
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg twice daily)
Trial: 2252170
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol and alfentanil
Trial: 2252170
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with nitrous oxide and enflurane at 1.3 MAC
Trial: 25483647
Drug: Bivalent CYD
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (± 15 days)
Trial: 25483647
Drug: Tetravalent blend
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent blend of CYD-1;3;4 and VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2)
Trial: 25483647
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis (JE) vaccine followed by CYD-TDV
Trial: 25483647
Drug: Tetravalent CYD
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent CYD vaccine (CYD-TDV)
Trial: 19236546
Drug: Combizym treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combizym treatment (2 weeks, two tablets post-meal, t.i.d.)
Trial: 19236546
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (2 weeks, two tablets post-meal, t.i.d.)
Trial: 15470286
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers (irbesartan, olmesartan medoxomil, telmisartan, valsartan) in combination with hydrochlorothiazide (40 mg/25 mg)
Trial: 15470286
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers with hydrochlorothiazide
Trial: 15470286
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with either angiotensin II receptor blockers or hydrochlorothiazide
Trial: 11828263
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose dacarbazine (arm A)
Trial: 11828263
Drug: High-dose dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose dacarbazine (arm B)
Trial: 2105243
Drug: hMG +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG + GH (24 IU on alternate days, total dose 144 IU)
Trial: 548209
Drug: Lecithin administration
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithin administration
Trial: 31182060
Drug: Running therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running therapy (exercise planned two times a week for 6 months)
Trial: 31182060
Drug: Running therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running therapy
Trial: 16774872
Drug: Charcoal (CC)
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Charcoal (CC) filter tipped cigarettes
Trial: 8901078
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg controlled-release (CR) oxycodone tablet
Trial: 8901078
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg immediate-release (IR) oxycodone solution
Trial: 1670668
Drug: Enzyme-linked immunosorbent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-linked immunosorbent assay (ELISA) for cerebrospinal fluid antibodies
Trial: 1670668
Drug: Antibody ELISA
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody ELISA in controls
Trial: 6666226
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ISDN (acute treatment)
Trial: 6666226
Drug: 4 X
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 X 60 mg ISDN (4 weeks treatment)
Trial: 22151932
Drug: 2% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hydroquinone cream
Trial: 27345284
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate 744 mg (delivering 400 mg isavuconazole)
Trial: 27345284
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate (oral administration)
Trial: 27345284
Drug: Isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Isavuconazonium sulfate 372 mg (delivering 200 mg isavuconazole) with esomeprazole 40 mg/day
Trial: 24594863
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily)
Trial: 22648731
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g per day of cis9,trans11 CLA‐enriched oil
Trial: 20079786
Drug: L-theanine (97
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (97 mg) and caffeine (40 mg)
Trial: 17639029
Drug: Linezolid (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (single and multiple dosing)
Trial: 16343096
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) administration after metformin treatment (group A)
Trial: 16343096
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) administration after laparoscopic ovarian drilling (LOD) (group B)
Trial: 26152410
Drug: Oral afoxolaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral afoxolaner chewable (NexGard) (dosage 3.1 - 6.2 mg/kg)
Trial: 22727976
Drug: Nebivolol 5mg
RxNorm normalized name: NEBIVOLOL 5MG TAB
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5mg daily (n=27)
Trial: 20943711
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Pharmacotherapy + Physiotherapy)
Trial: 19649309
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 to 300 mg/day)
Trial: 19649309
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 to 20 mg/day)
Trial: 15200753
Drug: Oxycodone/acetaminophen 10/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen 10/650 mg (single dose)
Trial: 15200753
Drug: Oxycodone/acetaminophen (multidose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen (multidose regimen)
Trial: 15200753
Drug: Oxycodone/acetaminophen
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone/acetaminophen
Trial: 15200753
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Rofecoxib or Oxycodone/acetaminophen)
Trial: 2915410
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl citrate (75 micrograms/h)
Trial: 2915410
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl citrate